CHABELINA FE Drug Patent Profile
When do Chabelina Fe patents expire, and when can generic versions of Chabelina Fe launch?
Chabelina Fe is a drug marketed by Novast Labs and is included in one NDA.
The generic ingredient in CHABELINA FE is ethinyl estradiol; norethindrone acetate. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CHABELINA FE?
- What are the global sales for CHABELINA FE?
- What is Average Wholesale Price for CHABELINA FE?
Summary for CHABELINA FE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| DailyMed Link: | CHABELINA FE at DailyMed |
US Patents and Regulatory Information for CHABELINA FE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novast Labs | CHABELINA FE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-28 | 202962-001 | Apr 15, 2020 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
